These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1240 related articles for article (PubMed ID: 34726500)

  • 1. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 2. Integrated budget impact model to estimate the impact of introducing selpercatinib as a tumor-agnostic treatment option for patients with
    Bhandari NR; Gilligan AM; Myers J; Ale-Ali A; Smolen L
    J Med Econ; 2024; 27(1):348-358. PubMed ID: 38334069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives.
    Bly CA; Molife C; Brown J; Tawney MK; Carter GC; Cinfio FN; Klein RW
    J Manag Care Spec Pharm; 2018 Jun; 24(6):534-543. PubMed ID: 29799326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pralsetinib: First Approval.
    Markham A
    Drugs; 2020 Nov; 80(17):1865-1870. PubMed ID: 33136236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer.
    Appukkuttan S; Farej R; Miles L; Purser M; Wen L
    J Manag Care Spec Pharm; 2021 Feb; 27(2):166-174. PubMed ID: 33141615
    [No Abstract]   [Full Text] [Related]  

  • 6. Exposure-Response Relationships for Pralsetinib in Patients with RET-Altered Thyroid Cancer or RET Fusion-Positive Nonsmall Cell Lung Cancer.
    Kassir N; McDougall D; Kuruvilla D; Kim S; Kumar S; Rahman A; Ruf T; Cheeti S; Ankrom W
    J Clin Pharmacol; 2024 Jun; 64(6):685-696. PubMed ID: 38337106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.
    Abraham I; Goyal A; Deniz B; Moran D; Chioda M; MacDonald KM; Huang H
    J Manag Care Spec Pharm; 2022 Apr; 28(4):435-448. PubMed ID: 35100006
    [No Abstract]   [Full Text] [Related]  

  • 8. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
    Subbiah V; Hu MI; Mansfield AS; Taylor MH; Schuler M; Zhu VW; Hadoux J; Curigliano G; Wirth L; Gainor JF; Alonso G; Adkins D; Godbert Y; Ahn MJ; Cassier PA; Cho BC; Lin CC; Zalutskaya A; Barata T; Trask P; Scalori A; Bordogna W; Heinzmann S; Brose MS
    Thyroid; 2024 Jan; 34(1):26-40. PubMed ID: 38009200
    [No Abstract]   [Full Text] [Related]  

  • 9. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
    Subbiah V; Shen T; Terzyan SS; Liu X; Hu X; Patel KP; Hu M; Cabanillas M; Behrang A; Meric-Bernstam F; Vo PTT; Mooers BHM; Wu J
    Ann Oncol; 2021 Feb; 32(2):261-268. PubMed ID: 33161056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan.
    Proudman D; Miller A; Nellesen D; Gomes A; Mankoski R; Norregaard C; Sullivan E
    JAMA Netw Open; 2020 Nov; 3(11):e2025866. PubMed ID: 33201235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
    Subbiah V; Hu MI; Wirth LJ; Schuler M; Mansfield AS; Curigliano G; Brose MS; Zhu VW; Leboulleux S; Bowles DW; Baik CS; Adkins D; Keam B; Matos I; Garralda E; Gainor JF; Lopes G; Lin CC; Godbert Y; Sarker D; Miller SG; Clifford C; Zhang H; Turner CD; Taylor MH
    Lancet Diabetes Endocrinol; 2021 Aug; 9(8):491-501. PubMed ID: 34118198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health Plan.
    Graham J; Earnshaw S; Burslem K; Lim J
    J Manag Care Spec Pharm; 2018 Jun; 24(6):544-553. PubMed ID: 29799327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers.
    Ali F; Neha K; Chauhan G
    Arch Pharm Res; 2022 May; 45(5):309-327. PubMed ID: 35598228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
    Gainor JF; Curigliano G; Kim DW; Lee DH; Besse B; Baik CS; Doebele RC; Cassier PA; Lopes G; Tan DSW; Garralda E; Paz-Ares LG; Cho BC; Gadgeel SM; Thomas M; Liu SV; Taylor MH; Mansfield AS; Zhu VW; Clifford C; Zhang H; Palmer M; Green J; Turner CD; Subbiah V
    Lancet Oncol; 2021 Jul; 22(7):959-969. PubMed ID: 34118197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Al Khayat MNMT; Armstrong N; Howick J; O'Meara S; Posadzki P; Ryder S; Ahmadu C; Konings SRA; Postma MJ; Duffy S; Wolff RF; van Asselt ADI
    Pharmacoeconomics; 2023 Apr; 41(4):353-361. PubMed ID: 36757608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations.
    Hernandez L; Young M
    J Manag Care Spec Pharm; 2023 Feb; 29(2):172-186. PubMed ID: 36373869
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan.
    Ramsey SD; Clarke L; Kamath TV; Lubeck D
    J Manag Care Pharm; 2006; 12(6):472-8. PubMed ID: 16925455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib.
    Russo GL; Bironzo P; Bennati C; Bonanno L; Catino A; Metro G; Petrini I; Russano M; Passaro A
    Crit Rev Oncol Hematol; 2024 Feb; 194():104243. PubMed ID: 38135019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
    Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
    Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With
    Kim J; Bradford D; Larkins E; Pai-Scherf LH; Chatterjee S; Mishra-Kalyani PS; Wearne E; Helms WS; Ayyoub A; Bi Y; Sun J; Charlab R; Liu J; Zhao H; Liang D; Ghosh S; Philip R; Pazdur R; Theoret MR; Beaver JA; Singh H
    Clin Cancer Res; 2021 Oct; 27(20):5452-5456. PubMed ID: 34045295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.